Here are 1-2 brief analogies for Mustang Bio (MBIO):

• It's like a clinical-stage Moderna, but focused on developing advanced cell and gene therapies for cancers and rare genetic diseases.

• Think of it as an early-stage Vertex Pharmaceuticals, but specializing in cell and gene therapies to tackle difficult-to-treat cancers and rare genetic conditions.

• MB-107 and MB-207 Gene Therapy: Programs targeting X-linked severe combined immunodeficiency, a rare genetic immune system condition.
• MB-102 CAR T Therapy: Designed to treat blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome.
• MB-106 CAR T Cell Program: A therapy under development for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
• MB-104 CAR T Therapy: Focused on treating multiple myeloma and light chain amyloidosis.
• MB-101 CAR T Cell Program: Developed for glioblastoma, a type of brain cancer.
• MB-103 CAR T Therapy: Targets glioblastoma multiforme and metastatic breast cancer to the brain.
• MB-105 CAR T Therapy: Aims to treat prostate and pancreatic cancers.
• MB-108 Oncolytic Herpes Simplex Virus: A next-generation oncolytic virus program for cancer treatment.

As a clinical-stage biopharmaceutical company, Mustang Bio (MBIO) is primarily engaged in the research and development of cell and gene therapies, and its pipeline products are not yet commercially available. Therefore, it does not currently have "major customers" in the traditional sense of selling approved products to individuals or other companies.

However, the company does engage in strategic collaborations and license agreements. Based on the provided background information, Mustang Bio has "license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH."

Should any of Mustang Bio's therapies reach commercialization, it is highly common for clinical-stage biotechs to partner with larger pharmaceutical companies for product distribution and commercialization. If an agreement with a company like CSL Behring (a major biopharmaceutical company) involves out-licensing of Mustang Bio's therapies for commercialization, CSL Behring could be considered a major partner or a "customer" for the commercial rights to those products.

Given the typical business model for clinical-stage biopharmaceutical companies and the specific mention of license agreements, if Mustang Bio were to sell or license its developed therapies, it would primarily do so to other companies. Among the entities mentioned in the license agreements, the most prominent public company that could act as a future commercial partner or licensee (and thus, a 'customer' for commercial rights or products) is:

• CSL Behring (Public Symbol: CSLBF)

In the scenario where Mustang Bio commercializes products directly without a major partner, its primary customers would then be hospitals and healthcare systems that administer specialized therapies.

• Minaris Regenerative Medicine GmbH
• SIRION Biotech GmbH

Manuel Litchman, M.D. President, Chief Executive Officer, and Interim Chief Financial Officer

Dr. Litchman has served as President and Chief Executive Officer of Mustang Bio since April 2017 and was appointed Interim Chief Financial Officer on November 15, 2024. Prior to joining Mustang Bio, he served as President and Chief Executive Officer of Arvinas, LLC, where he oversaw the advancement of the company's pipeline and executed multi-target discovery collaborations with Merck and Genentech. Dr. Litchman spent over 18 years at Novartis Pharmaceuticals Corporation, holding various leadership positions in oncology pipeline development, including Senior Vice President and Executive Global Program Head, CTL019, Cell & Gene Therapies Unit, where he led a collaboration on CAR T cells. Earlier in his career, he was a senior equity analyst at Ursus Capital and directed oncology/immunology clinical research at Hoffmann-La Roche Inc.

Michael Weiss. Executive Chairman of the Board

Mr. Weiss has served as Chairman of Mustang Bio's Board of Directors since May 2015. He is also the Executive Vice Chairman at Fortress Biotech and founded TG Therapeutics, Inc., where he serves as Executive Chairman, President, and Chief Executive Officer. From 2002 to 2009, Mr. Weiss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc., where he was instrumental in the acquisition and development of its lead drug, Auryxia, and secured a strategic alliance exceeding $100 million.

Lindsay A. Rosenwald, M.D. Director

Dr. Rosenwald has been a member of Mustang Bio's Board of Directors since its inception. He also serves as Chairman, President, and Chief Executive Officer of Fortress, a role he has held since December 2013. With over 23 years of experience as a biotechnology entrepreneur, Dr. Rosenwald has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. From 1991 to 2008, he was the Chairman of Paramount BioCapital, Inc.

David Jin. Director

Mr. Jin joined Mustang Bio's Board of Directors in October 2024. He currently serves as Chief Financial Officer and Head of Corporate Development at Fortress Biotech, and as Interim Chief Financial Officer and Chief Operating Officer of Avenue Therapeutics. His prior experience includes roles on the investment team at Barings (Private Equity & Real Assets), as Director of Corporate Development at Sorrento Therapeutics, and as Vice President of Healthcare Investment Banking at FBR & Co.

Greg Furrow, M.S., FRQA. Chief Quality Officer

Mr. Furrow joined Mustang Bio in January 2019, leading the company's Quality Organization. In this role, he oversees Clinical Quality Assurance, Manufacturing Quality Assurance, Quality Control Chemistry, Microbiology and Raw Material, and Quality Systems, ensuring compliance with FDA cGMP, GCP, GLP, and ICH requirements. Before Mustang Bio, Mr. Furrow was Vice President of Quality and Compliance at Southern Research and previously served as Vice President of Quality and Regulatory Compliance at WIL research.

1. Clinical Trial and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Mustang Bio's success is entirely dependent on its ability to successfully develop, test, and obtain regulatory approval for its product candidates. The development of cell and gene therapies is complex, costly, and time-consuming, with a high rate of failure at each stage of clinical development. All of Mustang Bio's product candidates, including MB-107, MB-207, MB-102, MB-106, MB-104, MB-101, MB-103, MB-105, and MB-108, are in various stages of development and have not yet received regulatory approval. There is no guarantee that any of these therapies will prove safe and effective in clinical trials or receive the necessary regulatory clearances for commercialization.
2. Funding and Capital Risk: Developing and commercializing cell and gene therapies requires substantial capital investment for research, clinical trials, manufacturing, and regulatory processes. As a company without any approved commercial products, Mustang Bio generates limited or no revenue from product sales. The company is reliant on its ability to raise additional capital through equity offerings, debt financing, strategic partnerships, or other sources to fund its operations and advance its pipeline. A failure to secure adequate funding when needed could significantly delay or halt the development of its product candidates and its business operations.
3. Intellectual Property and Competition Risk: Mustang Bio's business relies on its ability to protect its proprietary technology, much of which is obtained through license agreements with institutions such as Nationwide Children's Hospital, CSL Behring, Mayo Clinic, and Leiden University Medical Centre. There is a risk that these licenses could be challenged, terminated, or that the underlying intellectual property may not provide sufficient protection against competitors. Furthermore, the cell and gene therapy field is highly competitive, with numerous larger pharmaceutical and biotechnology companies developing similar therapies, which could impact Mustang Bio's ability to successfully commercialize its products, even if approved.

For Mustang Bio, Inc. (MBIO), a clinical-stage biopharmaceutical company currently without product revenue, the anticipated drivers of future revenue growth over the next two to three years are primarily tied to the successful advancement of its key pipeline candidates and strategic partnerships:

1. Advancement and Potential Commercialization of MB-106 for Waldenstrom Macroglobulinemia (WM): Mustang Bio's lead program, MB-106, a CD20-targeted CAR T cell therapy, is a primary focus. The company plans to initiate a registrational CAR T trial for relapsed or refractory WM in the second half of 2024, with potential topline results anticipated in the second half of 2026. Successful clinical development, including a potential Regenerative Medicine Advanced Therapy (RMAT) designation, and subsequent regulatory approval, would be a significant driver of future revenue, especially given the lack of FDA-approved CAR T therapy for WM.
2. Clinical Development and Potential Partnerships for MB-109 for Glioblastoma: Mustang Bio is focused on advancing MB-109, a combination therapy utilizing MB-101 (an IL13Rα2-targeted CAR T cell therapy) and MB-108 (an oncolytic herpes simplex virus). A novel clinical trial for recurrent glioblastoma and high-grade astrocytomas is planned for the second half of 2025. Both MB-101 and MB-108 have received Orphan Drug Designation from the FDA, enhancing their development pathway. Positive clinical outcomes could lead to lucrative partnerships or eventual commercialization, driving future revenue growth.
3. Monetization of the In Vivo CAR T Platform Technology: Mustang Bio continues to collaborate with Mayo Clinic on its in vivo CAR T platform technology. Successful progression and demonstration of this platform's potential could lead to strategic collaborations, licensing agreements, or the development of new product candidates. These early-stage partnerships and licensing deals would represent a form of revenue generation for a pre-revenue company in the specified timeframe.

Share Issuance

• Mustang Bio executed a 1-for-50 reverse stock split on January 16, 2025, significantly reducing the number of outstanding shares.
• In February 2025, the company priced a public offering of approximately 2.66 million shares of common stock (or equivalents) and accompanying warrants, aiming to raise approximately $8 million in gross proceeds for working capital and general corporate purposes.
• Shareholders approved the issuance of over 5 million shares under outstanding warrants in February 2025, a move intended to comply with Nasdaq listing rules and potentially raise capital.

Inbound Investments

• Mustang Bio recorded a gain of $1.5 million on the sale of property and equipment in connection with the sale of assets to uBriGene for the full year ended December 31, 2023.

Capital Expenditures

• Mustang Bio reported 'n/a' for Capital Expenditures in recent financial summaries, indicating minimal or no significant capital expenditures.
• In February 2025, Mustang Bio announced the sale of furniture, fixtures, and equipment for $1.0 million and an early exit from a facility, anticipating approximately $2.0 million in savings on lease-related payments.